We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Found Related to Asthma Susceptibility

By Biotechdaily staff writers
Posted on 25 Jul 2002
A gene called ADAM33, which codes for the production of the protease sub-family known as metalloproteases, has been linked through genetic screening to susceptibility to asthma. More...
The study was published in the July 10, 2002, online edition of Nature.

As part of an alliance with Schering-Plough (Kenilworth, NJ, USA) to develop therapies for asthma, researchers at Genome Therapeutics (Waltham, MA, USA) and the University of Southampton (UK) amassed clinical information and biological samples from over 450 families in the United States and the United Kingdom with members who suffer from asthma. Using the samples obtained, Genome Therapeutics employed its proprietary disease-specific gene identification platform to identify candidate genes linked to an increased likelihood of suffering from asthma.

Families with at least two children suffering from asthma were enrolled in the study. The affected subjects were required to have a diagnosis of asthma from a physician and be prescribed an asthma medication in order to be eligible. Following a genome-wide linkage analysis, the researchers identified several chromosomal regions as the likely location of the asthma genes, including chromosome 20p13. Further association studies on genes present in this chromosomal region confirmed that specific mutations in the ADAM33 gene were related to asthma susceptibility. The genetic analyses suggested that ADAM33 was involved in the generation of bronchial hyperresponsiveness (BHR).

"The airways in asthma patients undergo a number of changes such as thickening of the airway walls and subsequent narrowing of the airway passage,” stated Dr. Stephen Holgate, professor at the School of Medicine, University of Southampton, and a lead collaborator on the project. "These changes contribute to the overall airway responsiveness and related breathing problems in asthma. Our studies suggest ADAM33 plays a role in this remodeling and may underlie abnormalities in asthmatic airway function.”

The association of ADAM33 with BHR and possible links with airway remodeling offers new avenues of research into the underlying causes of asthma. Furthermore, discovery of susceptibility genes for asthma suggests that in the future it may become possible to identify those individuals who are predisposed to asthma and initiate therapy early to prevent or ameliorate the disease process before permanent changes occur.




Related Links:
Genome Therapeutics Corporation
Schering-Plough
University of Southampton

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.